Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)

The Quick Take
The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data when it placed Bright Minds' planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. An investigation is underway on behalf of DRUG investors who suffered losses. NEW YORK, Nov. 2,...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Archrock earnings beat by $0.03, revenue fell short of estimates
Business
Ryder System CFO Cristina Gallo-Aquino sells $342,740 in shares
Business
Earnings call transcript: BioMarin tops Q3 2026 estimates, but shares fall
Business
